Entera Bio

Company Overview

Snapshot

Founded in September 2009, Entera Bio operates with 11–50 employees. The company has raised a total of $58.9M across 7 funding rounds from 7 investors. In July 2018, Entera Bio became public on NASDAQ.

Business overview

Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics. Its proprietary technology enhances the absorption of large molecules in the gastrointestinal tract, addressing challenges related to oral drug administration. The company develops first-in-class, daily tablet protein and peptide replacement therapies, aiming to provide injection-free solutions for patients managing chronic diseases. Entera Bio operates within the Health Tech & Life Sciences sector, focusing on pharmaceuticals and drug delivery.

Strategic signal

In May 2026, Entera Bio's EB613, an oral PTH(1-34) anabolic for osteoporosis, was selected for a late-breaking oral presentation at the ENDO 2026 Annual Meeting, with additional oral peptide pipeline data also accepted. This indicates significant scientific validation and potential for its lead osteoporosis treatment, signaling strong progress in its clinical development and a promising future for its oral peptide platform.

Company Intelligence Q&A

What was a significant recent development for Entera Bio's EB613 program?

In May 2026, Entera Bio's EB613, a first-in-class oral PTH(1-34) anabolic for osteoporosis, was selected for a late-breaking oral presentation at the ENDO 2026 Annual Meeting. Additional oral peptide pipeline data was also accepted for presentation.

What were Entera Bio's financial results for the first quarter of 2026?

In May 2026, Entera Bio announced its first quarter 2026 financial results and provided updates across its oral peptide programs.

What was the outcome of Entera Bio's presentation at ASBMR 2025?

In September 2025, Entera Bio presented positive effects of EB613 on both trabecular and cortical bone in postmenopausal women with osteoporosis at ASBMR 2025.

What was the key outcome of the collaboration between Entera Bio and OPKO Biologics?

In September 2023, Entera Bio announced a collaboration with OPKO Biologics to develop oral peptide tablet formulations for obesity and intestinal malabsorption syndromes.

When did Entera Bio go public?

Entera Bio went public on NASDAQ in July 2018.